·¨¹ú¹ú¼Ò¿µ½¡ºÍҽѧÑо¿ÔºHalgandµÈ¿ËÈÕÍê³ÉµÄÒ»ÏîÑо¿Åú×¢£¬¸Îϸ°û°©£¨HCC£©»¼ÕßµÄÖ×Áö×éÖ¯Öпɼì³öHBV¸´ÖÆ£¬´ú±í¾ßÓÐת¼×éÑ§ÌØÕ÷µÄÖ×ÁöÇÖÕ¼ÐÔ½ÏÈõµÄÒ»¸öÑÇÐÍ£¬Ç°»ùÒò×éRNA£¨pgRNA£©¿É×÷Ϊ²¡¶¾¸´Öƺͻ¼ÕßÔ¤ºóµÄѸËÙ±ê¼ÇÎï¡£
¸ÃÏîÑо¿ÄÉÈë99ÀýHBsAgÑôÐÔ¡¢²¡¶¾Ñ§»ñµÃÒÖÖÆ¡¢½ÓÊÜÖ×ÁöÇгý»ò¸ÎÒÆÖ²µÄHCC»¼Õߣ¬ÆÊÎöÖ×ÁöºÍ·ÇÖ×Áö¸ÎÔàÑù±¾ÖеIJ¡¶¾ºÍϸ°û²ÎÊý£¬¶Ô×ÜHBV DNAºÍRNA¡¢¹²¼Û±ÕºÏ»·×´DNA£¨cccDNA£©ÒÔ¼°pgRNAµÈHBVÔ˶¯ÐÔ¸´ÖƵıê¼ÇÎï¾ÙÐмì²â¡£
Ч¹ûÏÔʾ£¬ÔÚ´ó´ó¶¼²¡ÀýµÄÖ×ÁöºÍ·ÇÖ×Áö¸Î×éÖ¯ÖУ¬¾ù¿É¼ì³ö×ÜHBV DNAºÍRNA¡£ÔÚ´ó´ó¶¼·ÇÖ×Áö¸Î×éÖ¯Öпɼì³öHBV cccDNAºÍpgRNA£¨¼ì³öÂÊ»®·ÖΪ66%ºÍ90%£©£¬Ïà±È֮ϣ¬Ö»Óв¿·ÖÖ×ÁöÑù±¾Öпɼì³öHBV cccDNAºÍpgRNA£¨¼ì³öÂÊ»®·ÖΪ39%ºÍ67%£¬P
¶Ô11ÀýÔ´ÓÚÓÎÀë»ùÒòÐÎʽµÄX»ùÒò¾ÙÐвâÐòÅú×¢£¬Ö×ÁöºÍÆ¥ÅäµÄ·ÇÖ×Áö¸Î×éÖ¯ÖеÄHBV»ùÒòÐͲ¢²»Ïàͬ£¬ÕâΪÖ×Áö×éÖ¯ÖеÄHBV¸´ÖÆÌṩÁ˽øÒ»²½Ö¤¾Ý¡£ÆÊÎöÅú×¢£¬Ö×Áö×éÖ¯Öпɼì³öpgRNAºÍcccDNA£¬Óë䱬·¢Ö×Áö΢Ѫ¹ÜÇÖÕ¼ºÍ»¼ÕßÉúÑÄÂʽϸßÓйء£Í¨¹ýAgilent΢ÕóÁжԻùÒò±í´ï¾ÙÐÐÆÊÎöÅú×¢£¬pgRNAÑôÐÔHCC£¬Æäϸ°ûÖÜÆÚºÍDNAÐÞ¸´±ê¼ÇÎïµÄˮƽ½ÏµÍ£¬²¢ÇÒ±í´ïHBVÊÜÌå-ÄÆÀë×Ó-Å£»Çµ¨ËṲתÔ˶àëÄ£¨NTCP£©£¬Åú×¢Ö×ÁöµÄ·Ö½âÓÅÒì¡£
ÐÅÔ´£ºWang Y, Xiong J, Niu M, et al. Statins and the Risk of Cirrhosis in Hepatitis B or C Patients: A Systematic Review and Dose-response Meta-analysis of Observational Studies. Oncotarget. 2017 Jul 27.


Ãö¹«Íø°²±¸ 35092602000113ºÅ